SOUTH PLAINFIELD, N.J., Nov. 9, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2015.
– 152 DMD patients now on Translarna TM (ataluren) commercial therapy
– Strong sales growth with YTD 9/30 Translarna revenues of $21.0M
– Phase 3 ACT DMD clinical trial results confirm clinical benefit of Translarna
– SMA program expected to resume clinical development in early 2016